GIFLF - Grifols, S.A.

Other OTC - Other OTC Delayed Price. Currency in USD
0.00 (0.00%)
As of 10:12AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close11.65
Bid0.00 x 0
Ask0.00 x 0
Day's Range11.65 - 11.65
52 Week Range7.90 - 21.00
Avg. Volume153
Market Cap7.501B
Beta (5Y Monthly)0.43
PE Ratio (TTM)35.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 03, 2021
1y Target EstN/A
  • GlobeNewswire

    Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD

    Now available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home without needing to visit a healthcare professionalAlpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases affecting around 16 million Americans and the fourth-leading cause of death in the U.S.1As the leader i

  • GlobeNewswire

    GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens

    SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi

  • CNW Group

    Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

    Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.